mRNA Technology; A Faster Route to Pharmaceutical Therapeutics?
The COVID-19 pandemic has provided scientists as well as the pharmaceutical industry an exceptional opportunity to perform a feat never seen in the pharmaceutical development process; two novel vaccines were developed within a year and passed regulatory approval for both efficacy and safety.
Letter to Editor
The COVID-19 pandemic has provided scientists as well as the pharmaceutical industry an exceptional opportunity to perform a feat never seen in the pharmaceutical development process; two novel vaccines were developed within a year and passed regulatory approval for both efficacy and safety.
These vaccines showed efficacies in regions above ninety percent and with almost five million doses administered in the United States of America alone, only twenty-nine allergic Letter to Editor reactions have been reported! (CDC.gov).
All the above was made possible by the usage of what is known as mRNA (messenger Ribonucleic Acid) technology. The thought-provoking question, Dear Editor is, why is this technology not been optimised to find pharmaceutical therapeutics for other diseases most especially cancer? with all the necessary genomic information available for the different forms of cancer?
- Acido Labile or Gastro Irritant Apis and Enteric Release in Galenic Practice: An Overview
- A Study on Knowledge, Attitude and Practice of Hand Hygiene among Healthcare Professionals at a Tertiary Care Hospital, India
- Influence of Inoculum Concentration on In Vivo Incubation Period of Emmia lacerata, Pathogenesis and Management of Wilt in Pepper (Capsicum annuum L.)
- Vanilla’s Chemistry
- Marine Anti-Cancer Compounds and Adverse Effects of Global Warming on Oceans: An Overview
- Serological Investigation of Chikungunya Virus Antibody among Malaria-Suspected Febrile Patients in Some Healthcare Facilities in Rivers State